Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

raludotatug deruxtecan

An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6) conjugated to deruxtecan, which is comprised of an enzymatically cleavable tetrapeptide-based linker and MAAA-1181a (DXd), the cytotoxic DNA topoisomerase I inhibitor derivative of exatecan, with potential antineoplastic activity. Upon administration of raludotatug deruxtecan, raludotatug targets and binds to CDH6-expressing tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of CDH6-expressing tumor cells. CDH6, a member of the cadherin family and overexpressed by a variety of cancers, plays a key role in tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CDH-6 ADC DS-6000a
anti-CDH6 ADC DS-6000a
anti-CDH6 antibody-drug conjugate DS-6000a
anti-CDH6/DXd ADC DS-6000a
Code name:DS 6000a
DS-6000
DS-6000a
DS6000a
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search